A single-center safety and tolerability study to evaluate the impact of treatment interruption on re-initiation of bifeprunox in subjects with schizophrenia or schizoaffective disorder

Trial Profile

A single-center safety and tolerability study to evaluate the impact of treatment interruption on re-initiation of bifeprunox in subjects with schizophrenia or schizoaffective disorder

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Jan 2015

At a glance

  • Drugs Bifeprunox (Primary)
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Adverse reactions
  • Sponsors Solvay
  • Most Recent Events

    • 30 Dec 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top